^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Ojjaara (momelotinib) (JAK2 inhibitor, JAK1 inhibitor, ACVR1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

    Excerpt:
    ...- Individuals with KRAS-mutated metastatic or recurrent non-small cell lung cancer...
    Trial ID:
    NCT02258607
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Discov
    Title:

    Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

    Excerpt:
    ...Both MRT67307 and CYT387 preferentially impaired the viability of KRAS-dependent A549 and HCC44 cells (IC50 ∼ 2 μmol/L) compared with KRAS-independent H1437 and H1568 cells…
    DOI:
    10.1158/2159-8290.CD-13-0646